title: Comprehensive analysis of temozolomide treatment for patients with glioma.
abstract: BACKGROUND
  This analysis was conducted to evaluate the efficacy and safety of temozolomide based chemotherapy in treating patients with glioma.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of temozolomide based regimens for patients with glioma were identified using a predefined search strategy. Pooled response rates (RRs) were calculated.
  
  
  RESULTS
  In temozolomide based regimens, 5 clinical studies including 152 patients with advanced glioma were considered eligible for inclusion. Four clinical studies included temozolomide. Systematic analysis suggested that, in all patients, pooled CR was 21% (32/152) , and PR was 21% (32/152). Grade 3/4 toxicity included neutropenia, thrombocytopenia, and anemia. No grade 3 or 4 renal or liver toxicity was observed. No treatment related death occurred with temozolomide based treatment.
  
  
  CONCLUSIONS
  This systematic analysis suggests that temozolomide based regimens are associated with mild response rate and acceptable toxicity for treatment of glioma patients.
authors.affiliation: Department of Radiology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China E-mail : ywb_wenbing@hotmail.com.
authors.forename: Wen-Bing
authors.initials: WB
authors.lastname: Yang
authors.forename: Bian-Zhi
authors.initials: BZ
authors.lastname: Xing
authors.forename: Hua
authors.initials: H
authors.lastname: Liang
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D011379:Prognosis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide